SCHEMBL5064310

SCHEMBL5064310

CSc1ncnc2sc(-c3ccc(CCl)cc3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
IKBKB O14920 3/20 0.35
TEK Q02763 3/20 0.32
FLT1 P17948 1/20 0.32
KDR P35968 1/20 0.32
ADORA3 P0DMS8 2/20 0.32
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
KDM4E B2RXH2 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5064152 0.90 PIK3CD (0.40) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL5064698 0.86 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1693615 0.86 PIK3CD (0.43) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL5065400 0.83 IKBKB (0.44) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL14031859 0.80 PIK3CD (0.37) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL5067450 0.77 EGFR (0.38) PIK3CDPIK3CAPIK3CBPIK3CGIKBKB
SCHEMBL5064776 0.74 ADORA3 (0.50) ADORA3KDM4E
SCHEMBL5064749 0.73 MAPT (0.49) ALDH1A1LMNAADORA3ADORA2AADORA1
SCHEMBL14031774 0.71 PIK3CD (0.34) PIK3CDPIK3CAPIK3CBPIK3CGIKBKB
SCHEMBL5068892 0.71 SSTR4 (0.40) PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 PIK3CD 3788/4885PIK3CA 2778/4885PIK3CB 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.